Copyright
©The Author(s) 2020.
World J Clin Cases. Mar 26, 2020; 8(6): 1065-1073
Published online Mar 26, 2020. doi: 10.12998/wjcc.v8.i6.1065
Published online Mar 26, 2020. doi: 10.12998/wjcc.v8.i6.1065
Table 2 Response to treatment with ruxolitinib
| Parameter | aGVHD, n = 10 | cGVHD, n = 28 |
| Overall response rate, n (%) | 10 (100) | 22 (82.1) |
| Median follow-up time in mo, median (range) | 2.5 (1.5–4) | 5 (1.5–10) |
| Time to best overall response in mo, median (range) | 1.0 (0.5–2.5) | 3.0 (1.0–9.5) |
| Time to best response for each organ system in d, median (range) | ||
| Skin | 28 (14–28) | 77 (7–147) |
| Digestive tract | 25 (14–60) | 259 (70–308) |
| Liver | 32 (21–42) | 42 (28–56) |
| Eye | - | 112 (42–182) |
| Oral cavity | - | 80 (28–168) |
| Lung | - | 91 (49–140) |
| Fascia | - | 91 (56–266) |
| Discontinuation of immunosuppressive agents after ruxolitinib, n (%) | 8 (80.0) | 21 (75.0) |
- Citation: Dang SH, Liu Q, Xie R, Shen N, Zhou S, Shi W, Liu W, Zou P, You Y, Zhong ZD. Ruxolitinib add-on in corticosteroid-refractory graft-vs-host disease after allogeneic stem cell transplantation: Results from a retrospective study on 38 Chinese patients. World J Clin Cases 2020; 8(6): 1065-1073
- URL: https://www.wjgnet.com/2307-8960/full/v8/i6/1065.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v8.i6.1065